**CCR-18-0945R1**

**SUPPLEMENTAL FIGURE LEGENDS**

**Supplemental Figure 1. Effect of ALT-803 treatment on white blood cell and lymphocyte counts in i.v. dose cohorts**

Circulating white blood cell (WBC x 1000 cells/μL, A) and absolute lymphocyte counts (ALC, cells/μL, B), before and during i.v. ALT-803 treatment administered on Days 1, 8, 15 and 22 of each 6-week cycle. The mean WBC or ALC values from subjects enrolled in each dose cohort [0.3 & 0.5 μg/kg (gray, 1 each), 1 μg/kg (brown, N=3), 3 μg/kg (lavender, N=3), and 6 μg/kg/dose (orange, N=3)] are shown in the left-hand panels. The mean maximal fold increases for each dose cohort are shown in the right-hand panels, where columns represent the mean of the maximal fold increase for each subject during treatment compared to baseline (Day 1). The results shown were limited to data through Cycle 2 Day 1 to limit complexity.

**Supplemental Figure 2. Circulating NK cell expansion during ALT-803 treatment**

Data shown are from subjects who received i.v. ALT-803 on Days 1, 8, 15 and 22 of each 6-week cycle. Absolute cell frequencies are shown as means grouped by dose cohort in left panels: 0.3 & 0.5 μg/kg (gray, 1 each), 1 μg/kg (brown, N=3), 3 μg/kg (lavender, N=3), and 6 μg/kg/dose (orange, N=3). Circulating total CD56+ NK cells (**A**), and subsets CD56bright (**B**) andCD56dim  (**C**) NK cell means for each dose cohort are represented by a single line/symbol. Right panels display mean maximal fold-increases during treatment compared to baseline (Day 1) for each dose cohort. The results shown were limited to data through Cycle 2 Day 1 to limit complexity, since maximal increases in NK cell counts occurred prior to that time point.

**Supplemental Figure 3. Effect of subcutaneous ALT-803 on circulating T cell expression of HLA-DR**

Mean % HLA-DR expression among CD8+ T cells (**A**) and CD4+ T cells (**B**) at Day 1 (pre-treatment) and maximal time points during treatment are shown. Each line represents the mean results grouped by dose cohort in left panels: 0.3 & 0.5 μg/kg (gray, 1 each), 1 μg/kg (brown, N=3), 3 μg/kg (lavender, N=3), and 6 μg/kg/dose (orange, N=3). Right panels display mean maximal fold-increases during treatment compared to Day 1 (pre-treatment) for each dose cohort.